Component 3 — Unlocking the Potential of Genomic Research: Precision Medicine

Scientists have known for years that the human genome holds important molecular keys to
understanding and overcoming disease. The information encoded in the DNA (i.e., genes) of
patients and their tumors has the potential to help us tailor treatment, postpone cancer
recurrence and, eventually, prevent tumor formation.
To unlock this tremendous potential, we must take advantage of state-of-the-art DNA sequencing technologies. We also must expand the IPCR’s resources for extracting and applying genetic data from blood, tumor and other biological samples. (Such samples will be collected from men with prostate cancer and men at high risk for the disease.)
Collectively, data from genetic analyses will serve as a valuable reservoir that researchers can plumb to better understand this complex disease: why some tumors are aggressive, for instance, while others are indolent; why some tumors respond well to certain therapies, while others quickly develop resistance.
IPCR researchers also intend to use genetic data to create better care plans for individual men, plans that include more accurate risk assessments and more informative, detailed diagnoses. Collectively, these plans will produce a “precision medicine” approach that involves customizing therapeutic strategies to enhance treatment responses and reduce side effects.